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AbstrACt
Introduction In the UK, smokers who use stop smoking 
services (SSSs) are four times more likely to stop smoking 
than smokers who do not. Attendance has declined, 
warranting the development of interventions to address 
this. StopApp is a novel, brief online behaviour change 
intervention designed to address common barriers to 
SSS attendance. It links to widely commissioned service 
management software that enables instant appointment 
booking at a user’s location and time of choice.
Methods and analysis A two-arm parallel group, individual 
participant feasibility randomised controlled trial of StopApp 
(intervention) compared with the standard promotion of 
and referral to SSSs (control). The study includes a nested 
qualitative process evaluation to assess the acceptability of 
the research processes, with a subsample of participants. 
Smokers aged over 16 years will be recruited via three routes: 
General Practice (GP), community settings and online. After 
consenting and the collection of baseline data, participants will 
be randomised to control or intervention groups. Participants 
in the intervention group receive a link to StopApp and those 
in the control group receive standard web-based information 
about the SSSs. All participants are told they can book a SSS 
appointment but are under no obligation to do so. Online 
follow-up 2 months post randomisation includes data on SSS 
use and carbon monoxide verified 4-week quit rates. The 
study aims to recruit 162 smokers.
Ethics and dissemination Ethics approval has been 
granted by the West Midlands—Edgbaston NHS Research 
Ethics Committee. The findings will be reported in 
conferences and peer-reviewed publications; and will be 
used to design the parameters necessary for a definitive 
trial to ascertain the effectiveness of StopApp at increasing 
booking and attendance at SSSs compared with existing 
methods for encouraging uptake.
IntroduCtIon 
Smoking remains a leading cause of mortality 
and morbidity worldwide.1 In addition, the 
direct costs of smoking to the UK National 
Health Service (NHS) have been estimated 
at between £2.7 billion and £5.2 billion, which 
is equivalent to around 5% of the total NHS 
budget each year.2 NHS stop smoking services 
(SSSs) provide free and tailored support to 
help people stop smoking, with the use of 
pharmacological and behavioural interven-
tions. The services are available to smokers 
over 12 years of age, including those who are 
pregnant. The effectiveness of SSSs is typically 
judged by the number of smokers who set 
a quit date and are abstinent from smoking 
4 weeks later, verified as standard by carbon 
monoxide (CO) testing.3 Four-week quit rates 
are a reliable predictor of long-term absti-
nence, with studies showing that collecting 
further follow-up data at 6 months provides 
only a modest increase in accuracy.4 Based 
on these measures, smokers who attend SSSs 
have been found to be four times more likely 
to quit smoking, than those who attempt to 
quit alone.5 
strengths and limitations of this study
 ► A feasibility randomised controlled trial with nested 
qualitative evaluation to ascertain acceptability of 
trial processes.
 ► Both objective and subjective measures are included 
to assess 4-week quit rates.
 ► Comparison of different sources of recruitment, 
including GP, community settings and online social 
media.
 ► Potential for selection bias including the requirement 
for participants to have access to the internet.
 ► Reliance on self-report data only for those in the 
control arm.
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Although most smokers want to quit, and between 22% 
and 31% of them will make at least one attempt to quit 
each year,6 SSSs currently reach only 5%–10% of the 
smoking population.7 In addition, despite the effective-
ness of SSSs,6 relative to the number of smokers, uptake 
has declined in recent years.8 This may be explained in 
part by the recent proliferation of electronic cigarettes 
(EC) leading people to switch to these instead of quitting 
smoking or instead of accessing support to quit. However, 
95% of SSS practitioners have encountered clients that 
use EC, suggesting that smokers do not view SSS and EC 
use as mutually exclusive.9 A third of smokers in England 
have used EC at least once,10 and while their use is asso-
ciated with significant reductions in numbers of ciga-
rettes smoked this has not led to an overall rise in quit 
attempts.11 Therefore, SSSs are still needed to support 
quit attempts.
A range of studies conducted since the commissioning 
of SSSs began, suggest that smokers (in particular those 
from lower socioeconomic status [SES] groups) are 
often unaware that SSSs exist, or what type of service 
they offer.12–16 Other barriers to accessing SSSs include 
holding beliefs that the services lack efficacy, and 
will be impersonal, judgmental and not tailored to 
individual needs. Additionally seeking help to stop is 
viewed as a sign of personal weakness.12–14 17 Typically, 
these barriers to service uptake have not formed the 
focus of interventions or health promotion campaigns 
targeted at smokers, possibly because access to SSSs 
had been robust and growing until recently.18 Research 
has shown, however, that booklets explaining the effi-
cacy of services19 and proactively recruiting smokers 
through General Practice (GP) can increase atten-
dance at SSSs and 4-week quit rates.20 A recent trial 
(Start2quit) assessing personalised risk information in 
the form of a letter from patients’ GPs and an offer of 
SSS taster sessions, was both effective and cost-effective 
at increasing SSS uptake.21 22
StopApp is a brief, novel web-based behaviour change 
intervention, developed with input from smokers across 
the SES spectrum, that targets the known barriers to 
service access to improve users’ motivation and capa-
bility to access SSS. StopApp links to an existing online 
booking and service management system used by phar-
macies offering SSS (PharmOutcomes), providing the 
opportunity to instantly book a first appointment at SSSs 
at a time and location to suit the user. A feasibility trial 
of StopApp (the MyWay study) is required to establish 
whether a future randomised controlled trial (RCT) can 
be achieved. This is especially necessary due to (1) the 
novelty of the StopApp intervention; (2) the potential for 
overlooking health inequalities associated with smoking 
when using digital interventions and (3) the limited 
extant research employing the required trial design 
across recruitment contexts that replicate real-world use 
of the intervention (including online and community 
settings).
Aims and objectives
The aim of the proposed research is to establish the feasi-
bility of a future RCT of the StopApp intervention.
Primary objective
To conduct a feasibility trial of StopApp to estimate 
recruitment and attrition rates of participants across three 
settings: GP surgeries, community settings and online; at 
baseline, intervention access and 2-month follow-up.
secondary objectives
Secondary objectives of the MyWay feasibility trial are to 
estimate the:
1. Acceptability of randomisation and the StopApp inter-
vention for participants.
2. Acceptability of the outcome measures and measures 
required for cost-effectiveness analyses in a future trial.
3. Key costs that would be incurred in delivering the in-
tervention and usual care, including a comparison of 
‘Did-not-attend’ (DNA) rates between each arm of the 
trial.
4. Feasibility of accessing SSS and GP data (if recruited 
via GP) on attendance, quit dates set and 4-week absti-
nence rates for trial participants.
5. Any differential recruitment and attrition rates across 
socioeconomic groups, age and gender.
6. Rate of SSSs attendance in the treatment and con-
trol groups to estimate the event rate of the primary 
outcome measure (eg, 4-week abstinence rate) for 
a future trial and to support future trial sample size 
calculations.
MEthods And AnAlysIs
study design
This study is a two-arm parallel group individual partici-
pant feasibility RCT of StopApp (intervention) compared 
with standard promotion of and referral to SSSs (control). 
The study will also have a nested qualitative process evalu-
ation to assess the acceptability of the research processes, 
randomisation, measures and the intervention with a 
subsample of participants.
Important changes to methods after pilot trial commencement
Shortly after the trial commenced, it was clear that recruit-
ment, in particular via GP practices, was slow. Obser-
vation of analytics data regarding visits to the research 
platform indicated that many potential participants were 
clicking though but not registering and taking part. In 
response to this, we decided to offer a financial incen-
tive (reimbursement) to participants joining the study, 
for their time to complete both measures in the form of 
a £10 e-gift token. It was intended that this would also 
reduce dropout at follow-up. The changes were approved 
by both the funder and ethics board. Participants already 
recruited to the study were contacted and offered the 
voucher.
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Participants
Eligibility criteria
All current smokers aged over 16 years registered with 
participating GP practices in Warwickshire, or accessing 
participating community services or viewing advertising 
for the study online, will be invited to take part, regardless 
of whether they have previously attended SSS. Access to 
the internet via a computer or smartphone to complete 
study measures, view intervention or control content and 
receive SMS reminders will be a requirement.
Setting
Smokers will be recruited from three settings across 
Warwickshire including six GP surgeries, a range of 
community settings (eg, children’s centres, libraries and 
well-being hubs) and online via social media platforms.
Recruitment
Recruitment will take place in three settings: GP prac-
tices, community settings and online.
Recruitment via GP surgery
The Clinical Research Network is supporting recruitment 
via GP surgeries. GP practices in Warwickshire have been 
invited to participate and of those who are interested, 
we will select six for the feasibility trial (ensuring in this 
process that we are reaching diverse groups). To remove 
the chances of contamination, we will contact one smoker 
per household only. Where two or more smokers cohabit, 
the resident whose first name is alphabetically first will 
be selected for invitation to the study and the other 
resident(s) will receive the control intervention after the 
study has ended.
Smokers (one per household) will be sent an email 
and/or text or letter (dependent on GP and patient 
communications set up) from their GP inviting them 
to take part in the ‘MyWay’ study. This will inform them 
that the study will investigate the best ways of using the 
internet to help people to stop smoking. Where a GP 
practice’s preferred method of contact with patients is via 
postal letter, ‘Docmail’ services will be used to distribute 
letters. For ethical reasons, we will not attempt to recruit 
people less than 16 years of age as they would typically 
require parental consent and parents may not be aware 
of their child’s smoking status. The email/text/letter will 
include brief information and a specific web link to the 
study website.
Recruitment via community settings
A range of community settings have agreed to promote 
the study. These include libraries, leisure centres, well-
being hubs, children’s centres, the family information 
service and the registrar’s office. A bus stop and bus-based 
advertising campaign will also be used to aid recruitment. 
We will supply each participating community setting with 
posters to display in prominent locations advertising 
the study with contact details of the research team and 
a community-setting specific web address to gain imme-
diate access to the study website for participants. We will 
train all relevant staff in participating locations about the 
study to enable them to answer any basic questions and to 
promote it confidently. We will also offer ad hoc research 
assistant presence for active promotion and recruitment 
on site. Where staff provides a leaflet, access to the study 
will be either through weblink to the project website or 
via contact with the research team. Where a research assis-
tant recruits on site, immediate access will be provided 
to the study via tablet computers. Participants will have 
the option to gain access to the project website without 
having to commit to participating.
Online recruitment
The marketing and communications team at Warwick-
shire County Council (WCC) are supporting all 
the online recruitment activities. Specifically, they are 
providing support for online promotion of the study via 
social media, targeted email marketing, Google adver-
tising and all WCC internal and external channels, such 
as press releases and electronic newsletters. These ads will 
appear to anyone in the Warwickshire area searching for 
health-related products or services. We will run a 3-month 
long campaign to advertise the study. In addition, partici-
pating community settings will promote the study online 
via their social media channels. 
Participants from all 3 recruitment sites will be provided 
with an online 'Participant Information Sheet' (PIS) prior 
to agreeing to take part, and have the option to gain 
access to the project website without having to commit to 
participating. 
Figure 1 Flow diagram illustrating participant’s route 
through the project.
 o
n
 2 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028721 on 8 April 2019. Downloaded from 
4 Fulton E, et al. BMJ Open 2019;9:e028721. doi:10.1136/bmjopen-2018-028721
Open access 
Interventions
Please refer to figure 1 for a flow diagram illustrating 
participants’ routes through the study. Eligible smokers 
will be recruited from one of three settings and provided 
with a link to the study webpage. This is delivered via 
Coventry University’s secure bespoke study manage-
ment software (‘eNgage’). Participants will be required 
to endorse mandatory consent statements. Participants 
then complete a baseline questionnaire, which will take 
approximately 20 minutes to complete. Following rando-
misation, both groups will receive a link with nearly iden-
tical content, taking participants to either the control 
website or to the StopApp (intervention group). At the 
same time, an email containing the link will also be sent 
to participants to allow them to access the material at a 
later date. A reminder email will also be sent to all partici-
pants 2 weeks later. Participants in both conditions will be 
told that if they wish to book an appointment at the SSS, 
then they are free to do so, but in taking part are under 
no obligation to do so. Participants in both groups will 
have continued access to the content, although they have 
been designed to be used on a single basis. Two months 
after baseline data collection all participants will be asked 
via email to complete an online follow-up questionnaire, 
and invited to take part in a nested qualitative study 
(telephone interviews) to investigate the acceptability of 
the MyWay trial. The number of participants from both 
arms taking part in the interviews will be capped at n=30. 
Consenting participants will complete one telephone 
interview after follow-up. Staff from recruitment settings 
(community and GP) will also be invited to participate 
in telephone interviews about their involvement in the 
study. Participants will be informed that should they wish 
to withdraw from the study at any time they should contact 
the research team using the project email address (details 
provided on eNgage and within email communication). 
An email with a link to the information leaflet provided 
to the control group will be given to anyone who contacts 
us after the end of the period of recruitment to the study.
At the first appointment, stop smoking advisors will 
be prompted to ask participants: (1) to confirm they 
are taking part in the MyWay study/trial; and if yes, (2) 
whether they consent to the research team accessing data 
on their SSS use, which will be stored anonymously and 
(3) how they heard about the SSS. This is to ensure that 
consent for the access of service use data is collected by 
the data controller in order that they can create a report 
on SSS use for trial participants who consent to this. The 
report will identify appointments booked via StopApp 
and sent to a secure  NHS. net email address, from which 
names will be cross-referenced against participant ID 
numbers before the data is transferred into the anony-
mous database maintained by the research team.
Qualitative study
At baseline, following randomisation, we will ask all 
participants (using a single yes/no question) if they are 
interested in participating in a brief follow-up telephone 
interview at the end of the study, regardless of whether or 
not they end up completing the study. For all participants 
that indicate an interest, we will request a contact tele-
phone number and their consent to process this informa-
tion in addition to personal data already collected. For 
participants providing this consent, we will select approx-
imately 30 feasibility RCT participants and invite them 
to participate in the process evaluation interviews. We 
will apply maximum variation sampling using the demo-
graphic characteristic data collected, in order to ensure 
good representation of the range of consenting partici-
pants. In addition, staff contacts generated at recruitment 
sites during data collection will be invited to participate 
in process evaluation interviews. Invitation will be by tele-
phone and those who wish to participate will be sent a 
follow-up email directing them to a new study page on 
eNgage (separate pages will be generated for staff and 
trial participants). On clicking ‘join project’, they will 
receive a message telling them that they will be contacted 
by a member of the research team to set up a mutually 
convenient time for the interview. The interviews will 
explore acceptability and user experience in line with 
each of the identified research objectives. They will last 
approximately 30 min and be audio recorded. Interview 
transcripts will be transcribed verbatim. Participants will 
be able to withdraw their consent for up to 2 weeks after 
participation in the interview, prior to data analysis. We 
will allow data analysis to determine saturation point and 
when to stop, but anticipate conducting up to 30 inter-
views. All qualitative data will be subject to thematic anal-
ysis23 assisted by NVivo software.
Intervention arm
StopApp is a web-based self-administered behaviour 
change intervention designed to address the barriers that 
smokers typically face in accessing SSSs.17 24 Information 
about users’ previous quit attempts and use of SSSs is used 
to tailor the way in which subsequent content is framed 
to address any negative perceptions. Users can instantly 
book an appointment at a time and location of their 
choice, or get a reminder to reaccess the intervention at 
a later date. StopApp is linked to the online outcomes 
reporting systems owned by Pinnacle Healthcare Ltd 
and used by SSSs in pharmacies (PharmOutcomes) in 
Warwickshire (and many other local authority areas 
across the UK). These secure systems support service 
providers in recording standard SSS outcome data, such 
as quit dates and CO verified 4-week quit rates. In addi-
tion to applying coproduction and usability methods, 
the content of the StopApp intervention was system-
atically developed using the Behaviour Change Wheel 
approach.25 Specific content within the app delivers 17 
Behaviour Change Techniques (BCT's) identified as most 
useful for supporting SSS access behaviour.17 24
Control arm
The control group will receive access to a webpage 
displaying Warwickshire’s standard SSS provision 
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information (‘Quit4good’). The control website does not 
link to an online booking system and does not provide 
tailored routing according to the types of barriers a 
smoker may have to SSS access. It has not been system-
atically designed to address barriers to service access and 
is not underpinned by a theory of behaviour change or 
identified BCTs.
data management
Study recruitment, consent, randomisation, provision of 
intervention or control content and questionnaire data 
collection, all take place within ‘eNgage’—Coventry 
University’s bespoke online research software hosted on 
their secure server. eNgage is an online research plat-
form that includes the research pages, study information, 
consent and research team contact details. It is devel-
oped to work seamlessly with other web applications. On 
‘joining’ a project, participants provide their full name 
and email address, on which a unique participant ID 
is created. Participants are then directed to Qualtrics 
(a separate questionnaire data inputting software) to 
complete the baseline, and later the follow-up measures. 
Participants are then directed back to eNgage where they 
are randomised to experimental conditions. Analytics 
data on participant use of the research materials (and 
intervention or control content) is collected by software 
called ‘Matomo’. All data is linked by the unique partic-
ipant ID.
outcomes
Baseline measures
An online baseline questionnaire includes questions 
regarding demographic information (including age, 
gender, profession, ethnicity and postcode—for purposes 
of identifying indices of multiple deprivation scores); 
current smoking status and tobacco products used (type 
and quantity, including EC use); previous use of SSS; 
ease of internet access and motivation to quit, measured 
using the one-item ‘Motivation to Stop Scale’ (MTSS)26 
and a single-item Likert scale.27 Health-related quality 
of life data will be collected using the EuroQOL Five 
Dimensions Questionnaire (EQ5D-5L)28 instrument to 
inform the health economic analysis29, and the ICECAP-A 
(ICEpop CAPability measure for Adults)30 31 instrument 
to measure general well-being.
Two-month follow-up measures
An online follow-up questionnaire will assess self-re-
ports of whether participants booked an appointment 
and attended a SSS, set a quit date and reached a 
4-week abstinence, and what prompted them to book 
an appointment. Pinnacle Health Ltd will run a search 
of the PharmOutcomes system for MyWay participants 
(where they consented) and provide the researchers with 
objective service use data. This will allow an assessment 
regarding the validity of sourcing objective evidence of 
booking, attendance (DNA rates), quit dates set and CO 
tested 4-week quits. We will also assess the feasibility of 
collecting follow-up measures of motivation using the 
MTSS and a single-item Likert scale27, the EQ5D-5L 
instrument and the ICECAP-A instrument. In addition, a 
bespoke resource use questionnaire will be administered, 
to gain insight into the costs both to individuals and to the 
public purse of resources accessed as a result of the use of 
the StopApp compared with the control.
Data on costs associated with the intervention versus usual care
We will gather, through trial processes, data on the costs 
associated with delivering the intervention (eg, web 
hosting and text messages) and usual care (eg, telephone 
calls taken to book in appointments). We will also collect 
data on costs and resource use associated with promoting 
the intervention and usual care (eg, marketing through 
social media and posters on buses).
sample size
The primary objective of this study is to assess the feasi-
bility of recruitment to a potential future definitive RCT 
and therefore formal power analysis is not appropriate. 
However, in order to determine the target sample size, we 
have drawn on two sources based on the primary outcome 
of attendance at SSS (attend vs does not attend SSS). 
Researchers have recommended that external pilot and 
feasibility studies with binary outcome measures recruit at 
least 60 participants in each group (minimum n=120) and 
a maximum of 100 participants in each group (maximum 
n=200).32 In addition, our sample size calculations, based 
on similar definitive RCT data about recruiting smokers to 
trials via letters from their GPs,22 suggested that we would 
need to enrol 980 smokers to detect a 7% difference in 
attendance at SSS between control and intervention arms 
in a definitive trial. Based on this estimate, any trial would 
need to recruit 1.8 participants per day to achieve the 
required recruitment in 18 months. We plan to recruit 
for 3 months, and based on needing to recruit 1.8 partic-
ipants per day, we need to reach a required sample size 
of 162 participants (54 per setting). With a sample size of 
162, the recruitment rate of smokers for a full RCT will be 
estimable with a precision (95% CI width) of ±5%. We will 
compare recruitment rates across the three recruitment 
sources.
randomisation
Sequence generation, allocation and blinding
Randomisation will be carried out through the study 
website during months 12–14 of the study. For this 
purpose, a digital bespoke randomisation algorithm 
(embedded within the study website) has been developed 
in collaboration with our statistician and the clinical trials 
unit at the University of Warwick. This will autorandomise 
at the individual level (1:1) using minimisation to ensure 
balance. The research team and participants will be blind 
to condition assignment.
Statistical methods
Feasibility and acceptability of all measures will be assessed 
by the level of completeness and by follow-up qualitative 
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interviews with a subsample of participants. We will calcu-
late recruitment rate via GP surgeries as a percentage of 
those recruited from those smokers identified on partici-
pating GPs lists. We will calculate recruitment via commu-
nity and online settings as the time taken and spend 
required to recruit 54 participants and/or the number 
recruited and spend over 3 months. We will calculate the 
average recruitment rate per day across the three settings. 
We will provide percentage rates for attrition across each 
recruitment setting at each of baseline, intervention/
control access and 2-month follow-up.
We will look at the observed difference between inter-
vention and control groups for bookings and attendance 
at SSS and use this data to support estimates for the 
required sample size for a definitive trial and to help to 
determine future trial efficacy. We will assess the level of 
completeness of all measures and run missing value anal-
ysis to determine whether any missing data are missing at 
random or whether patterns of missing data may indicate 
a problem with measures. We will report observed and 
self-reported bookings, attendances, quit dates set and 
4-week quits across the intervention and control groups, 
and the proportion of participants agreeing to allow 
access to SSS data relating to smoking status and SSS 
attendance. We will report on numbers of higher versus 
lower SES status participants recruited as well as age and 
gender, and assess using Chi-Square (χ2) analysis whether 
SES status, age or gender are associated with attrition 
at baseline, intervention/control access and 2-month 
follow-up.
Patient and public involvement
We have a patient and public involvement (PPI) group of 
11 smokers from a range of SES backgrounds who have 
contributed to the design of this feasibility trial, including 
the participant information sheet and measures. At least 
one member of the PPI group will be present at study 
steering committee meetings throughout the duration of 
the feasibility trial.
dIsCussIon
The main purpose of the proposed feasibility study is 
to determine the necessary requirements for successful 
study design and data collection such that a definitive full 
trial can be conducted. This will largely be determined by 
whether one or more of the recruitment settings are able 
to produce the required sample size for a future main 
trial. We will also use data collected about SES, age and 
gender of those recruited and lost through attrition to 
understand whether SES is associated with retention in 
the trial. A future potential RCT will enable us to estab-
lish whether and to what extent StopApp is effective and 
cost-effective at increasing SSS bookings and attendance 
in comparison to standard methods of service promotion.
Although leaflet and letter-based methods are effective 
for increasing recruitment to SSS’s, StopApp is unique in 
that its systematic evidence-based development,17 24 aims 
to address all identified barriers to accessing SSSs while 
also taking account of (or will take account of during 
evaluation) affordability, practicability, effectiveness (and 
cost-effectiveness), acceptability, side effects (and safety) 
and equity.25 If effective and cost-effective, StopApp is 
instantly scalable because PharmOutcomes is already 
used extensively across the UK. Therefore, it would likely 
be delivered at even lower ongoing cost than interven-
tions such as the cost-effective Start2quit letter and taster 
session,21 22 and if well marketed could reach many more 
than the 5%–10% of smokers that services have reached 
so far.7
Given that public health budgets are under increasing 
pressure, and evidence suggests smokers seeking help 
themselves are more successful at stopping than those 
referred by others,33 it will become increasingly important 
that SSSs are used by more of those making quit attempts 
each year to enhance their chances of success. Imple-
menting inexpensive strategies to help this to happen 
will, therefore, maximise effectiveness and help to ensure 
optimal use of increasingly tight public health resources.
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